Efficacy and Safety of Nusinersen in Children With Later-Onset Spinal Muscular Atrophy (SMA): End of Study Results From the Phase 3 CHERISH Study

Released by

Biogen

5 of 7

Previous slideNext slide

Creator

Biogen

Category

Healthcare

Published

2017

DownloadShareAsk AI

Slides

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Transcriptions

#1#2#3#4#5#6#7

Download to PowerPoint

Download presentation as an editable powerpoint.

Download